Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

This study is testing a combination of two immunotherapy drugs — iparomlimab and tuvonralimab (together called QL1706) — in women with hormone receptor-positive, HER2-negative breast cancer that has come back or spread, and is no longer responding well to standard hormone therapies. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative - Your cancer has measurable areas on imaging - You have received no more than two prior chemotherapy regimens and no more than two CDK4/6 inhibitor treatments for advanced disease - You have a good performance status (ECOG 0-1) **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your cancer has spread to the brain - You have severe organ function problems Talk to your doctor to see if this trial is right for you.